Eric Dube, Ph.D.

Notable Quotes

We believe in the potential of FILSPARI to make a meaningful difference in the lives of people living with FSGS and are encouraged by the productive engagement with the FDA.

from First FSGS drug hits FDA delay after 8-year clinical journey · Updated Jan 30

I'm a two-time rare cancer survivor. I know what it feels like to be diagnosed and told 'there's no treatment option available.' You'll often hear me say, I'm impatient for patients.

from First FSGS drug hits FDA delay after 8-year clinical journey · Updated Jan 30

The fourth quarter closed out an exceptional year of commercial execution with FILSPARI, as our teams were able to reach a record number of patients with IgAN, reinforcing its role as foundational therapy.

from First FSGS drug hits FDA delay after 8-year clinical journey · Updated Jan 30

Stories

First FSGS drug hits FDA delay after 8-year clinical journey

Rule Changes

Leading company through FDA review process

No FDA-approved treatment for focal segmental glomerulosclerosis (FSGS) has ever existed. For the 40,000 Americans with this rare kidney disease—which drives half of patients to kidney failure within a decade—the only options have been off-label immunosuppressants with mixed results. On January 13, 2026, that was supposed to change. Instead, the FDA extended its review of sparsentan by three months, requesting more data on clinical benefit. The announcement triggered a 33% intraday stock plunge and sparked multiple shareholder investigations into potential securities law violations. Two weeks later, CEO Eric Dube sold $1.56 million in company stock, a transaction drawing scrutiny given its timing.

Updated Jan 30

Eric Dube, Ph.D.

Notable Quotes

Stories

First FSGS drug hits FDA delay after 8-year clinical journey

Help us improve Newzino